Nick zheng (@pick1998_2) profile picture

Biotech stock trading and investing for 35 years. PhD in biology, MS in computer science.

Las Vegas
Joined November 2011
Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)Photo by Nick zheng (@pick1998_2)
$PEPG sinks to 3.7, now we can buy 26% cheaper than 2nd offering price at 5. Market is brutal to early stage biotech stocks. Added enough to average down to 4.3.
2
2
19
2,919
$PEPG next step is to add at 3, try to get averaged down to 3.5. Then enough, and wait until mid 2027 (high dose at 12.5mg/kg data due for DM1).
1
5
854
$XBI drops to 145, +19% YTD, outperforms SP500 or nasdaq. However, biotech broad market is not so positive. Many tiny-small biotech stocks keep sinking to new lows. Those without clear positive late stage clinical data or approved drugs hardly advance.More new lows than new highs
2
4
1,153
$HELP produced very good data on efficacy in 1st pIII trial as adjunctive (add-on) therapy for MDD, even similar to placebo-adjusted effect by $DFTX as monotherapy), which is more impressive. HLP003 is deuterated psilocin, it should change chemistry of psilocin. Better than $CMPS
1
2
16
2,961
$HELP correction: HLP003 is deuterated psilocin, it should NOT change chemistry of psilocin. Better than $CMPS
1
5
812
$PEPG added at 4.5, averaging down to 4.95. Will add more at 4. Surely, the lower, the better.
2
11
2,735
$LQDA $PGEN when a biotech company makes a superior product, no worry about your market. Those of inferior products often expands the total market with their marketing cost to help you accelerate revenue growth.
2
23
2,767
$NVDA CEO Jansen Huang got ousted for his affair with a lady, wiping out hundreds of billions of market value. What could be sadder than this for a successful American company? It proved traditional Chinese wisdom again: For a man, nothing is more risky than a lady.
1
8
1,084
$LQDA 50s again, amazing recovery from recent low at 20s. Buy when market is at panic when the company has a good product. $PGEN will recover to new highs, too.
1
10
1,456
$SVRA is moving up to PDUFA next Fri, but still at 5.
3
1,089
$PEPG will good data (~50% splicing, acceptable safety) from high dose cohort (12.5mg/kg) in 1H27 and 1 year follow-up from lower dose qualify NDA for accelerated approval? if yes, this stock is way too cheap under $1B valuation right now.
1
7
1,392
$PEPG initiated a long pos at 5.5. 46% splicing correction for DM1 is so good. It's pII trial at dose of 10mg/kg. high dose 12.5mg/kg data 1H27. From pI single dose study, 15mg/kg achieved 53.7% mean splicing. So I expect 12.5mg/kg dose should give around 50% splicing. Strong Buy
2
1
24
2,867
$REPL $PGEN my top pos. Crazy movement in price. Just two months ago, $PGEN is a big winner; now it has given back almost all gain; while $REPL has surged to my #1 position. To balance portfolio, I am selling some $REPL and buy more $PGEN. Both have best products for unmet needs
3
15
1,813
$INO $70m offering at 1.05 before discount, ripping off shareholders again, esp. naive new retail investors who bought it on FDA approval. i only see it will bleed faster and dilute more before seeing any revenue. this 70m will be gone even the confirmatory trial starts.
6
3
15
3,383
$XBI down 5%, and $PGEN, a profitable biotech stock, down another 20%. What a disaster day :-) But I hold all my bio stocks that are at commercial stage or near FDA approval such as $LRMR $SVRA $QURE
2
1
17
2,362
CITIZENS $PGEN Weakness following competitor approval is stark overreaction and presents compelling opportunity to buy $PGEN PAPZIMEOS complete response rate of 51% compared to 27% complete response rate achieved with VOCERYQ $INO PAPZIMEOS label also #broader than VOCERYQ
7
2
22
5,427
$CNTB does it and its Chinese partner Simere Pharm have a better version of Dupixent? Simere submitted NDA for atopic dermatitis in China (approval by April 2027). Dupixent sales total 5.7B euro 3Q26: bloomberg.com/news/articles/…
1
2
1,586
Why $CNTB stock price stays under 1? Please share some of your insights please.
1
721
Replying to @jy201506
Thanks for sharing, so basically $IOVA is competing with $REPL now in refractory melanoma, and $REPL has a an easier to provide and widely anticipated therapy at $1.4b enterprise value and $IOVA has a $3.7b enterprise value with all the additional hassle. got it
1
1
4
834
$IOVA revenue forecast:
1
1
9
1,994